Genotype–Serotype Interactions Shed Light on Genetic Components of Inflammatory Bowel Diseases. Issue 2 (27th September 2018)

• Record Type: Journal Article
• Authors: Ben-Shachar, Shay; Finezilber, Yael; Elad, Hofit; Rabinowitz, Keren; Goren, Idan; Isakov, Ofer; Yanai, Henit; Dotan, Iris
• Is Part Of: Inflammatory bowel diseases. Volume 25:Issue 2(2019)
• Page Start: 336
• Page End: 344
• Publication Date: 2018-09-27
• Subjects: inflammatory bowel disease (IBD) -- Crohn's disease -- ulcerative colitis -- NOD2 -- ATG16L1 -- serologic markers; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izy231
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Background: We evaluated the impact of variations in ATG16L1 and NOD2 and genes on serologic responses in patients with inflammatory bowel disease (IBD). Methods: We recruited 308 IBD patients: 130 with Crohn's disease (CD), 67 with ulcerative colitis (UC), 111 with UC and an ileal pouch (UC-pouch), and 74 healthy controls. NOD2 variants (1007 fs, G908R, R702W) and the ATG16L1 A300T variant were analyzed. The antiglycan antibodies anti– Saccharomyces cerevisiae (ASCA), antilaminaribioside (ALCA), antichitobioside (ACCA), and antimannobioside carbohydrate (AMCA) were analyzed by enzyme-linked immunosorbent assay. Results: Antichitobioside was positive in 28% of patients with CD carrying the ATG16L1 A300T variant (either heterozygote or homozygote) compared with only 3% in those without the variant ( P < 0.001). Anti– Saccharomyces cerevisiae was positive in 86% of patients with CD carrying the NOD2 1007fs variant compared with 36% in those without the variant ( P < 0.001). UC-pouch patients with the NOD2 1007fs variant had elevated ASCA and ALCA levels compared with those without the variant (50% vs 7%, P = 0.004, and 50% vs 8%, P = 0.006, respectively). Importantly, ATG16L1 A300T and NOD2 variants were not associated with serologic responses in healthy controls and unoperated UC patients. Multivariate analysis demonstrated that these genetic variants are the main factors associated with specific antiglycan antibody levels in CD and pouch patients. Conclusions: Genetic variants may have disease-specific phenotypic (serotypic) effects. This implies that genetic risk factors may also be disease modifiers.